V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedAbout V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine
V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine is a phase 2 stage product being developed by Merck for Ebola. The current trial status is completed. This product is registered under clinical trial identifier NCT03031912. Target conditions include Ebola.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03031912 | Phase 2 | Completed |
Competing Products
20 competing products in Ebola